Jason Weber, PhD

Jason Weber

Researcher Background

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Molecular Oncology, Washington University School of Medicine

Training

  • 1997 - 2001: Postdoctoral associate, Howard Hughes Medical Institute, St. Jude Children's Research Hospital, Memphis, TN

Education

  • 1997: PhD, cell and molecular biology, Saint Louis University, St. Louis, MO

Research & Selected Publications

Research Interest

The p53 protein requires communication between upstream activators in order to sense when a cell is under stress. One such activator is the ARF tumor supressor. These two proteins are among the most frequently affected genes in human cancer. We are interested in understanding the individual contribution of these proteins to the development of human cancers and how they may be regulated by upstream signals.

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.
Authors:

Kong T, Mabry A, Highkin M, one or more additional authors omitted Weber JD, one or more additional authors omitted Ma CX

Journal & Year:

Nat Commun • 2026

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.
Authors:

Kong T, Mabry A, Highkin M, one or more additional authors omitted Weber JD, one or more additional authors omitted Ma CX

Journal & Year:

Nat Commun • 2026

ADAR1 Regulates Lipid Remodeling to Dictate Ferroptosis Sensitivity.
Authors:

Kung CP, Terzich ND, Ilagan MXG, one or more additional authors omitted Weber JD

Journal & Year:

bioRxiv • 2025

ADAR1 Regulates Lipid Remodeling to Dictate Ferroptosis Sensitivity.
Authors:

Kung CP, Terzich ND, Ilagan MXG, one or more additional authors omitted Weber JD

Journal & Year:

bioRxiv • 2025

Elevated Type I Interferon Signaling Defines the Proliferative Advantage of ARF and p53 Mutant Tumor Cells.
Authors:

Mabry A, Kuzmicki CE, O'Brien A, Maggi LB, Weber JD

Journal & Year:

Mol Cell Biol • 2025

Elevated Type I Interferon Signaling Defines the Proliferative Advantage of ARF and p53 Mutant Tumor Cells.
Authors:

Mabry A, Kuzmicki CE, O'Brien A, Maggi LB, Weber JD

Journal & Year:

Mol Cell Biol • 2025

Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor cells.
Authors:

Mabry A, Kuzmicki CE, O'Brien A, Maggi LB, Weber JD

Journal & Year:

bioRxiv • 2024

Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor cells.
Authors:

Mabry A, Kuzmicki CE, O'Brien A, Maggi LB, Weber JD

Journal & Year:

bioRxiv • 2024